Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: J Clin Pathol. 2019 Oct 31;73(4):197–203. doi: 10.1136/jclinpath-2019-206117

Figure 2.

Figure 2

TIM-3, LAG-3 and VISTA expression evaluated by flow cytometry. (A) Patient A was obtained from the peripheral blood of an adult male with leukaemic involvement by PTCL, NOS. Both monocytes (CD14+) and T cell lymphoma cells (CD3+, 99% lymphoma cells) were gated for further analysis, as indicated. (B and C) Purified CD3+ lymphocytes from a healthy donor and purified CD4+ T cells from Sezary patients (patients B and C; ≥85% lymphoma cells). Expression of TIM-3, LAG-3 and VISTA was evaluated in resting conditions and on activation with anti-CD3/CD28 beads (24 hours), as indicated. (D) PTCL, NOS cell lines (T8ML1) were similarly evaluated in resting conditions and after CD3/CD28 activation. (E) Expression of TIM-3, LAG-3 and VISTA by different T cell lymphoma lines. (F) Table summarises the level of expression of the proteins analysed within the different T cell lymphoma lines. ALCL, Anaplastic large cell lymphoma; CTCL, Cutaneous T-cell lymphoma; LAG-3, lymphocyte-activation gene 3; PTCL, peripheral T cell lymphoma; TCR, T-cell receptor; TIM-3, T cell immunoglobulin-3; VISTA, V-domain Ig-containing suppressor of T cell activation.